Advertisement
UK markets closed

  • FTSE 100

    8,245.37
    -39.97 (-0.48%)
     

  • FTSE 250

    20,555.37
    -160.51 (-0.77%)
     

  • AIM

    793.53
    -3.01 (-0.38%)
     

  • GBP/EUR

    1.1771
    +0.0030 (+0.26%)
     

  • GBP/USD

    1.2725
    -0.0067 (-0.53%)
     

  • Bitcoin GBP

    54,358.36
    -1,501.09 (-2.69%)
     

  • CMC Crypto 200

    1,431.46
    -47.24 (-3.19%)
     

  • S&P 500

    5,355.86
    +2.90 (+0.05%)
     

  • DOW

    38,922.36
    +36.19 (+0.09%)
     

  • CRUDE OIL

    75.43
    -0.12 (-0.16%)
     

  • GOLD FUTURES

    2,318.30
    -72.60 (-3.04%)
     

  • NIKKEI 225

    38,683.93
    -19.58 (-0.05%)
     

  • HANG SENG

    18,366.95
    -109.85 (-0.59%)
     

  • DAX

    18,557.27
    -95.40 (-0.51%)
     

  • CAC 40

    8,001.80
    -38.32 (-0.48%)
     
REAL ESTATE:

10 bargain properties going under the hammer

Buying a home at auction can save you money, but preparation is key

Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024

Bio-Path Holdings, Inc.
·2-min read
Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc.

HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) --  Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 15, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024 and to provide a business overview.

To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.

ADVERTISEMENT

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:
                        
Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369